Conference Reports

Chicago, Illinois, US
10 November 2018 - 12 November 2018
Munich
19 October 2018 - 23 October 2018
Bangkok, Thailand
28 September 2018 - 01 October 2018
Munich
25 August 2018 - 29 August 2018
Surabaya
08 August 2018 - 11 August 2018
Amsterdam, the Netherlands
23 July 2018 - 27 July 2018
Orlando, Florida, US
22 June 2018 - 26 June 2018
Stockholm, Sweden
14 June 2018 - 17 June 2018
Amsterdam
13 June 2018 - 16 June 2018
San Diego, California, US
18 May 2018 - 23 May 2018
Los Angeles, California, US
21 April 2018 - 27 April 2018
Chicago, Illinois, US
14 April 2018 - 18 April 2018
Geneva
11 April 2018 - 14 April 2018
Barcelona
18 March 2018 - 20 March 2018
Chicago, Illinois, US
16 March 2018 - 20 March 2018
Copenhagen
16 March 2018 - 19 March 2018
Hong Kong
10 March 2018 - 11 March 2018
Orlando, Florida
10 March 2018 - 12 March 2018
San Diego, California
16 February 2018 - 20 February 2018
Las Vegas, Nevada
18 January 2018 - 20 January 2018
Los Angeles, California, US
24 January 2018 - 26 January 2018
San Francisco, California, US
18 January 2018 - 20 January 2018
Hong Kong
20 January 2018 - 20 January 2018
Abu Dhabi
04 December 2017 - 08 December 2017
Atlanta, Georgia, US
09 December 2017 - 12 December 2017
San Antonio, Texas, US
05 December 2017 - 09 December 2017
Anaheim, California, US
11 November 2017 - 15 November 2017
Singapore
17 November 2017 - 19 November 2017
Singapore
06 October 2017 - 08 October 2017
Milan, Italy
09 September 2017 - 13 September 2017
Singapore
13 July 2017 - 15 July 2017
San Diego, California, US
09 June 2017 - 13 June 2017
Chicago, Illinois, US
02 June 2017 - 06 June 2017
Geneva
05 May 2017 - 08 May 2017
Houston, Texas, US
22 February 2017 - 24 February 2017
Amsterdam
27 January 2017 - 30 January 2017
San Diego, California
03 December 2016 - 06 December 2016
San Antonio, Texas
06 December 2016 - 10 December 2016
Vienna
04 December 2016 - 07 December 2016
12 November 2016 - 16 November 2016
Singapore
20 July 2016 - 24 July 2016
New Orleans, Louisiana
10 June 2016 - 14 June 2016
Geneva
13 April 2016 - 16 April 2016
San Antonio, Texas, US
08 December 2015 - 12 December 2015
Orlando, Florida, US
05 December 2015 - 08 December 2015
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Prof. Cheuk-Chun Szeto, Dr. Winston W. S. Fung, 25 Jan 2018
A 65-year-old lady with a background of type 2 diabetes, hyperlipidaemia and chronic immune thrombocytopenia presented to us with a 2-week history of generalized malaise and myalgia. Shortly after the onset of myalgia, she was noted to have reduced urine output and the urine was described as dark in colour. Her regular medications included prednisolone, danazol, simvastatin, metformin, and human insulin. Upon further questioning, the patient admitted that her compliance to simvastatin and danazol used to be poor. However, she recently started to take both medications regularly after repeated education.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Jairia Dela Cruz, 26 Jun 2018
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Pearl Toh, 20 Mar 2018
Not only does treatment with the PCSK9* inhibitor alirocumab reduces cardiovascular (CV) events along with plunges in LDL-C levels, it was also associated with a reduced risk of all-cause mortality compared with placebo in patient with a recent acute coronary syndrome (ACS) and persistently high cholesterol despite maximal statin therapy, according to top-line results from the ODYSSEY** Outcomes trial.